NSE · GUFICBIO
Gufic BioSciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹252 Cr with net profit ₹21 Cr — a 8.16% net margin, versus 6.73% the period before.
Shareholding
As of 2026-06-30
- Promoter72.5%
- Public23.36%
- FII0.46%
- DII3.68%
29,753 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.67× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #37 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,80,131 Cr | 38.63 | 5.75 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,462 Cr | 213.45 | 3.44 | 11.27% | 12.06% |
| Zydus Lifesciences Ltd. | ₹1,11,232 Cr | 20.48 | 4.1 | 18.59% | 18.86% |
| Lupin Limited | ₹1,10,705 Cr | 19.46 | 4.93 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,06,384 Cr | 52.81 | 6.53 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,554 Cr | 432 | 2.51 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹91,552 Cr | 99.39 | 2.41 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,545 Cr | 294.21 | 5.03 | 16.66% | 15.65% |
| Biocon Ltd. | ₹69,409 Cr | 539.11 | 2.01 | 1.14% | 2.3% |
| Gufic BioSciences Ltd.(this company) | ₹3,835 Cr | 176.12 | 5.77 | 9.66% | 6.8% |
AI analysis
AI-generated · google/gemini-2.5-flashGufic BioSciences Ltd. is listed on the Indian markets with a market capitalization of Rs 3949 Cr. The company reported revenue of Rs 823.43 Cr and a profit margin of 6.8%. Earnings per share (EPS) stood at Rs 6.4. The latest 52-week trading range for the share price was between Rs 268 and Rs 448.
Positives
- +Promoter holding increased from 65.75% in Sep 2018 to 72.50% in Mar 2026.
- +Debt-to-equity ratio is 0.59.
- +No promoter shares are pledged, with a promoter pledge of 0% as of Mar 2026.
- +The company has a positive profit margin of 6.8%.
Negatives
- −The price-to-earnings (PE) ratio of 180.62 is high.
- −Revenue growth was 1.6%, indicating slow top-line expansion.
- −Return on equity (ROE) is 9.66%, which is below 10%.
- −Return on capital employed (ROCE) is 11.45%, indicating moderate capital efficiency.
Financial Performance
Gufic BioSciences Ltd. recorded a total revenue of Rs 823.43 Cr with a revenue growth rate of 1.6%. The company's profit margin for the period was 6.8%. Over the past year, quarterly revenues have shown fluctuations, with Mar 2026 reporting Rs 251.82 Cr and Dec 2025 reporting Rs 231.41 Cr.
Profitability & Returns
The company's earnings per share (EPS) is Rs 6.4. Return on equity (ROE) was 9.66% and return on capital employed (ROCE) stood at 11.45%. The profit margin was 6.8%.
Balance Sheet
Gufic BioSciences Ltd. has a book value of Rs 66.31. The debt-to-equity ratio is 0.59, indicating its reliance on debt financing relative to equity. No information on total debt or cash reserves was provided.
Ownership & Pledges
As of Mar 2026, promoters held 72.50% of the shares. Public shareholding was 23.24%, while institutional holdings (DII and FII combined) were 4.26%. There were no promoter shares reported as pledged.
Shareholding History
Promoter holding has seen an increase from 69.98% in Dec 2016 to 72.50% in Mar 2026. Public shareholding decreased from 29.59% in Dec 2016 to 23.24% in Mar 2026. FII holding has varied, reaching 0.42% in Mar 2026 from 0.37% in Dec 2016.
Data as of — price: 2026-07-31 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.